Current Rheumatology Reports

, Volume 2, Issue 3, pp 256–261

Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?

  • Michelle Petri

DOI: 10.1007/s11926-000-0088-5

Cite this article as:
Petri, M. Curr Rheumatol Rep (2000) 2: 256. doi:10.1007/s11926-000-0088-5


The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains highintensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful “proving ground” of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Michelle Petri
    • 1
  1. 1.Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations